Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Primary Immunodeficiency Clinical Trials

A listing of Primary Immunodeficiency medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (51) clinical trials

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric subjects = 17 years of age and at least 9 [20%] obese subjects with ...

Phase

Do you have Primary Immunodeficiency Syndrome and currently take Hyqvia for treatment? We’re currently looking for participants for a non-interventional research study. A non-interventional study is one that does not alter your doctor’s treatment decisions, but rather collects data over time on how a certain drug is used.

Phase

Primary Immunodeficiency (PI) diseases are a family of congenital disorders of the immune system that lead to an increase in frequency of infections, notably, but not limited to, bacterial infections of the respiratory tract. Patients with PI do not have the healthy antibodies to fight off the infections and often ...

Phase

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

Chronic hepatitis is a major health problem with hepatitis B virus (HBV) affecting upwards of 350 million people worldwide and over one million in the United States, while hepatitis C virus (HCV) infects as many as 70-130 million people worldwide, and approximately 4.1 million (1.6% of the US population) in ...

Phase N/A

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Based on diagnosis and clinical history, a determination of the most appropriate regimen will be made based on the following prep plans: Arm A: Fully Myeloablative Preparative Regimen, Arm B: Reduced Toxicity Ablative Preparative Regimen, Arm C: Reduced Intensity Conditioning, Arm D: No Preparative Regimen

Phase N/A

IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia

Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after HyQvia administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods: The first period is a one-week ramp-up period. ...

Phase

Natural History of Noncirrhotic Portal Hypertension

Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induced portal hypertension which includes the development of gastrointestinal varices, portal hypertensive gastropathy, splenomegaly, sepsis and ...

Phase N/A

Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

This protocol is designed as an adjunct to other NIAID IRB approved protocols that allow for genetic testing, which may include those that are screening protocols for patients with rare primary immunodeficiency or immunodysregulation disorders. Patients deemed of sufficient research interest after review of outside medical records, clinical evaluation, and ...

Phase N/A

Genetic Basis of Primary Immunodeficiencies

The purpose of this study is to evaluate patients with primary immunodeficiency disorders to identify patients with mutations of the genes for the following proteins: Jak3, STAT1, STAT4, interleukin-7, interleukin-7 receptor, interleukin-12 receptor subunits, and others. Patients will undergo screening history, physical examination, and clinical laboratory evaluation at referring institutions ...

Phase N/A

Efficacy Safety Tolerability Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age 2 to <16 years) participants with primary immunodeficiency disease (PIDD).

Phase